Navigation Links
Osteotech Reports 2008 Third Quarter Financial Results
Date:11/7/2008

thousands)

September 30, December 31,

2008 2007

Assets

Cash and cash equivalents $19,331 $ 22,777

Accounts receivable, net 20,420 19,353

Deferred processing costs 34,478 30,850

Inventories 1,375 1,171

Prepaid expenses and other current assets 2,842 3,957

Total current assets 78,446 78,108

Property, plant and equipment, net 35,427 34,508

Other assets 12,081 7,735

$125,954 $120,351

Liabilities and Stockholders' Equity

Accounts payable and accrued liabilities $ 21,659 $ 19,364

Current maturities of capital lease obligation 871 807

Total current liabilities 22,530 20,171

Capital lease obligation 13,407 14,069

Other liabilities 7,165 7,083

Total liabilities 43,102 41,323

Stockholders' equity 82,852 79,028

$125,954 $120,351


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
2. Osteotech to Present at Sidoti Conference in San Francisco
3. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
4. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
5. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
6. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
7. Osteotech to Present at the Sidoti Conference in New York
8. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
9. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
10. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
11. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... LAUSANNE , Switzerland ... Debiopharm International SA (Debiopharm), part of Debiopharm Group ™ ... prescription drugs that target unmet medical needs ... that preclinical data on the investigational compounds ... inhibitor) will be presented at the 2015 ...
(Date:4/16/2015)... Fairleigh Dickinson University ( FDU ... become the Executive Director of the Rothman Institute ... kick-off of the Initiative for Patient Centered Innovation ... under the Rothman Institute of Innovation and Entrepreneurship ... collaboration with FDU’s School of Pharmacy’s Center for ...
(Date:4/16/2015)... Washington (PRWEB) April 16, 2015 ... Applied Cancer Science and Resolution Bioscience, Inc. today ... to co-develop a novel, blood-based, clinic ready, Next ... cancer (NSCLC). The collaboration is the first to ... RET, and ROS1 fusions in blinded plasma samples ...
(Date:4/16/2015)... 2015 CCI Global Channel Management, the ... planning management software for major tech and telecom vendors, ... survey of channel vendor programs in software, hardware, and ... How the top IT vendors in each segment ... coming year. , Assessment of the state ...
Breaking Biology Technology:Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 2CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 3
... Researchers at Rensselaer Polytechnic Institute and Polyset ... that could lead to dramatic cost savings and ... packaging. , Along with allowing enhanced performance and ... material, called polyset epoxy siloxane (PES), should also ...
... Jan. 28 MedPredict has published,"Thought Leader Insight ... insight for pharma and biotech companies with a,stake ... this disease area., "Given the size of ... for long-term disease control, it is not surprising ...
... Breathing Resistance,Exerciser has successfully accomplished the crossover ... the respiratory therapy market for,COPD patients. Jorge ... the most compact (4") breathing exerciser, originally ... size portable respiratory,exerciser to increase lung capacity ...
Cached Biology Technology:New polymer could improve semiconductor manufacturing, packaging 2New Report Tackles the Changing Landscape for Alzheimer's Diagnostics and Treatments 2It's Good News for The Lungs! 2
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... a specific gene plays a role in the weight-gain response ... animal study suggests that blocking this gene could one day ... disorders, such as diabetes and liver damage, in humans. ... production of this gene, called protein kinase C beta (PKC ...
... University of Liverpool (UoL) have secured a 1.4 million project ... malaria. The project, funded by the Wellcome Trust, aims ... a novel enzyme in the respiratory chain of Plasmodium ... enzyme within the parasite is not found in humans, thereby ...
... Cardiovascular Research Institute, Colchester, Vermont have found that ... inhibitor type-1 (PAI-1) is profibrotic. The results, ... Experimental Biology and Medicine , implicate PAI-1 ... 2 diabetes, as a factor contributing to the ...
Cached Biology News:Researchers uncover 'obesity gene' involved in weight gain response to high-fat diet 2Researchers uncover 'obesity gene' involved in weight gain response to high-fat diet 3LSTM and UoL secure £1.4m ($2m) to develop new 'magic bullet' antimalarial drug 2Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes 2
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... formulated for covering tissue sections and cell preparations ... alcohol insoluble end products. UltraMount Plus ... Red or AEC that require an aqueous mounting ... DAB. No heating is required prior to use. ...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... III is intented for ... PBMCs (or lysed whole ... intracellular kinases and appropriate ... Applications: Intracellular Staining (Flow) ...
Biology Products: